Skip to main content
. 2019 Apr 23;120(11):1037–1044. doi: 10.1038/s41416-019-0461-2

Table 1.

Baseline characteristics of all included patients, associated with CAIX combined with vascular density

Variable All (n = 385) Not CAIX >1% and high vascular density (n = 322) CAIX >1% and high vascular density (n = 63) P*
Age (years)a 64.0 (34.0–89.0) 64.3 (34.0–89.0) 63.5 (43.0–88.0) 0.634
Follow-up (months)a 65.1 (0.0–156.0) 63.8 (0.0–156.0) 71.6 (0–148.0) 0.125
Grade
 Low 318 (82.6) 270 (83.9) 48 (76.2) 0.142
 High 67 (17.4) 52 (16.1) 15 (23.8)
Histology
 EEC 372 (96.6) 314 (97.5) 58 (92.1) 0.028
 NEEC 13 (3.4) 8 (2.5) 5 (7.9)
FIGO stage
 I–II 363 (93.8) 305 (94.7) 58 (92.1) 0.406
 III–IV 22 (5.7) 17 (5.3) 5 (7.9)
Myometrial invasion
 <50% 258 (67.2) 218 (67.9) 40 (63.5) 0.494
 ≥50% 126 (32.8) 103 (32.1) 23 (36.5)
LVSIb
 No 243 (62.8) 200 (90.1) 43 (84.3) 0.234
 Yes 30 (7.8) 22 (9.9) 8 (15.7)
Lymph nodesc
 No metastasis 263 (68.0) 223 (95.7) 40 (95.2) 0.891
 Metastasis 12 (3.1) 10 (4.3) 2 (4.8)
Adjuvant treatment
 No 154 (40.0) 143 (44.8) 22 (34.9)
 Radiotherapy 200 (51.9) 161 (50.0) 39 (61.9) 0.084
 Chemotherapy 31 (8.1) 18 (5.6) 2 (3.2) 0.429
Recurrence
 No 338 (87.8) 289 (89.8) 49 (77.8)
 Yes 47 (12.2) 33 (10.2) 14 (22.2) 0.008
 Local 14 (3.6) 12 (3.7) 2 (3.2) 0.830
 Regional 16 (4.2) 13 (4.0) 3 (4.8) 0.792
 Distant 31 (8.1) 19 (5.9) 12 (19.0) <0.001
Death
 No 335 (87.0) 284 (88.2) 49 (77.8)
 Yes 50 (13.0) 38 (11.8) 14 (22.2) 0.027
 EC-related 21 (5.5) 12 (3.7) 11 (17.5) <0.001

CAIX carbonic anhydrase IX, EEC endometrioid endometrial carcinoma, NEEC non-endometrioid endometrial carcinoma, FIGO International Federation of Gynaecology and Obstetrics, LVSI lymphovascular space invasion, EC endometrial carcinoma

*P value of the Mann–Whitney U test for continuous, and χ2 test and Fisher’s exact for categorical variables

aMedian values (range)

bBased on 273 patients

cBased on 275 patients